Lupus drug anifrolumab under safety watch: does it raise infection or cancer risk?
NCT ID NCT07000110
First seen Mar 07, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This study observes about 3,200 adults with moderate-to-severe lupus to see if those taking anifrolumab have more serious infections or cancers than those on standard treatment. Researchers will track hospitalizations, infections needing IV antibiotics, and new cancer diagnoses. The goal is to better understand the long-term safety of anifrolumab in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGCopenhagen, 23000, Denmark
-
Research Site
RECRUITINGCharenton-le-Pont, 94220, France
-
Research Site
RECRUITINGEssen, 45128, Germany
-
Research Site
RECRUITINGBarcelona, 08007, Spain
Conditions
Explore the condition pages connected to this study.